fbpx

Can we teach old drugs new tricks? – Repurposing of neuropharmacological drugs for inflammatory skin diseases.

Can we teach old drugs new tricks? – Repurposing of neuropharmacological drugs for inflammatory skin diseases.

Related Articles

Can we teach old drugs new tricks? – Repurposing of neuropharmacological drugs for inflammatory skin diseases.

Exp Dermatol. 2019 Jun 07;:

Authors: Abels C, Soeberdt M

Abstract
Despite the “hype” for monoclonal antibodies, the so called biologics, which added significant value to the therapeutic armamentarium of dermatologists and improved the life of many patients, but may exhibit significant adverse effects, the vast majority of dermatological patients suffering from Atopic Dermatitis or Psoriasis is still treated topically. Thus, there is a huge need for locally applied, locally acting drugs for inflammatory skin diseases with better risk-benefit profiles compared to topical corticosteroids or calcineurin inhibitors. Drug repositioning is a complex process, but offers advantages, in particular for indications with lower revenues. In this viewpoint the neuroendocrine system of the skin is described as an attractive drug target because it contributes significantly to neutralizing external noxious agents prior to inducing immune or vascular changes leading to the clinical signs of skin inflammation, e.g. itch and erythema. In addition, epidermis and dermis are accessible for topically applied products which may act locally without pharmacodynamically relevant systemic exposure limiting adverse events. Moreover, since numerous drugs have been evaluated for various CNS diseases, some failed and some approved, this resource should be exploited for repurposing as anti-inflammatory drugs for topical application, e.g. cannabidiol, fingolimod or asimadoline. Finally, a screening algorithm is shared which gives direct evidence of links between drug and inflammatory skin diseases. This article is protected by copyright. All rights reserved.

PMID: 31173654 [PubMed – as supplied by publisher]

বাংলা简体中文繁體中文EnglishFrançaisDeutschहिन्दीItaliano日本語한국어मराठीPortuguêsਪੰਜਾਬੀРусскийEspañolSvenskaతెలుగుไทยTürkçeУкраїнськаTiếng Việt